La Jolla Pharmaceutical Company

Theravance Biopharma Inc. will eliminate debt from its balance sheet and improve its cash balance through the sale of its interest in Theravance Respiratory Company LLC (TRC) – representing an 85% sh

Innoviva, Inc. continues to branch out from collecting royalties on inhaled respiratory medicines commercialized by GlaxoSmithKline Pharmaceuticals Ltd. to a company also developing and commerciali

Windtree Therapeutics, Inc. hopes eventually to bring its first-in-class SERCA 2a activator istaroxime to market for treatment of acute heart failure, but along the way to getting potentially approva

No matter how tumultuous the times, the novel drugs and biologics approved by the US FDA in 2020 show the continuation, and even acceleration of previous themes as the novel drug and biologic class be